Jump to content

Page values for "Atomoxetine"

"Medicines" values

1 row is stored for this page
FieldField typeValue
genericStringAtomoxetine
brandStringStrattera
structureFile
classesList of String, delimiter: ,[[:Category:NRIs|Selective norepinephrine reuptake inhibitor (NRI)]] [[:Category:ADHD medicines|ADHD medicine]]
mechanismString
usesString'"`UNIQ--vote-00000013-QINU`"'
starting_doseStringChildren ≤70 kg: 0.5 mg/kg/day, titrate to 1.2 mg/kg/day after 3 days. Adults and children >70 kg: 40 mg PO once daily for 3 days, then 80 mg/day, then if needed 100 mg/day after 2-4 weeks
preparationsStringCapsules 10, 18, 25, 40, 60, 80, 100 mg
fda_maxString100 mg/day (adult); 1.4 mg/kg/day or 100 mg total (pediatric, whichever lower)
pill_idText
routesList of String, delimiter: ,Oral
onsetStringADHD effect emerges over 1-2 weeks (slower than psychostimulants); full effect 4-6 weeks
durationString24 hours (once-daily or split BID dosing)
halflifeString~5 hours in extensive CYP2D6 metabolizers; ~21 hours in CYP2D6 poor metabolizers'"`UNIQ--ref-00000014-QINU`"'
bioavailabilityString~63% (oral; extensive first-pass)'"`UNIQ--ref-00000015-QINU`"'
pregnancyStringLimited human data.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup>
legalString[[USLegal:Prescription only|Rx-only]] in US. '''Not a controlled substance''', the principal clinical selling point versus psychostimulant ADHD options. Carries the antidepressant-class '''Boxed Warning''' for suicidal ideation in pediatric patients'"`UNIQ--ref-00000016-QINU`"'